Previous 10 | Next 10 |
EyePoint Pharmaceuticals (EYPT): Q1 GAAP EPS of -$0.50 beats by $0.01.Revenue of $7.3M (-2.5% Y/Y) misses by $0.54M.Financial Outlook: Expects the cash on hand at March 31, 2021 and expected net cash inflows from the product sales to fund the current and planned operations through the en...
- EYP-1901 DAVIO study for the potential treatment of wet AMD dosed first patient in January; study remains on track for initial data in Q4 2021; -Completed $115.1 million follow-on financing in February 2021; -Net product revenues of $6.8 million versus $4.7 million...
WATERTOWN, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference c...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips OK, let’s wrap our heads around this one: Ocugen (NASDAQ: OCGN ) has a $1.4 billion market capitalization. But its entire pipeline is still in preclinical trials for various ophthalmic conditions. And it’...
In this article, I will go through the end of year earnings call and presentation. With the balance sheet in good shape, management is putting majority of their focus toward their pipeline. Shares are a Buy at this level, but always keep your position sizes in check with any small...
EyePoint Pharmaceuticals, Inc. (EYPT) Q4 2020 Earnings Conference Call March 4, 2021 8:30 AM ET Company Participants George Elston – Chief Financial Officer Nancy Lurker – President and Chief Executive Officer Jay Duker – Chief Strategic Scientific Officer Scott Jones ...
EyePoint Pharmaceuticals (EYPT): Q4 GAAP EPS of -$1.07 misses by $0.90.Revenue of $7.13M (-17.4% Y/Y) misses by $11.16M.Press Release For further details see: EyePoint Pharmaceuticals EPS misses by $0.90, misses on revenue
- $115.1 million follow-on financing completed in February 2021 - First patient dosed in Phase 1 clinical trial with EYP-1901 in January 2021 - $16.5 million monetization of ILUVIEN Royalty with $15 million applied to reduction in debt obligations in December...
WATERTOWN, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference ca...
EYPT has had great products for some time now. They finally got their financing in order and the market loved it. Even after essentially doubling their share count, their price started going up again the next day. For further details see: EyePoint Pharmaceuticals: Time F...
News, Short Squeeze, Breakout and More Instantly...
EyePoint Pharmaceuticals Inc. Company Name:
EYPT Stock Symbol:
NASDAQ Market:
EyePoint Pharmaceuticals Inc. Website:
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical tria...
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R...